Vertex: cross-border access for the specialty portfolio

Quick orientation

Vertex Pharmaceuticals Incorporated is a US-headquartered biotechnology company based in Boston, Massachusetts. Vertex's specialty footprint has historically been dominated by the cystic fibrosis CFTR modulator franchise (Trikafta, Symdeko, Orkambi, Kalydeco, and the newer Alyftrek). The 2023 FDA approval of Casgevy, co-developed with CRISPR Therapeutics, made Vertex the originator of the first FDA-approved CRISPR-based gene-editing therapy. The 2025 launch of Journavx for acute pain represents the first non-opioid sodium-channel pain mechanism approved in decades.

Portfolio in cross-border NPP scope

Trikafta (elexacaftor, tezacaftor, and ivacaftor)

Triple-combination CFTR modulator approved for cystic fibrosis in patients age 2 and older with at least one F508del mutation or another responsive mutation. US WAC at the standard adult dose runs at approximately $323,000 per patient per year. Cross-border requests come heavily from CF patients in MENA and India where local Trikafta supply is intermittent, where the pediatric weight-band presentation is not stocked, or where the patient's specific CFTR mutation is on the responsive list but not yet locally recognized.

Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor)

Next-generation triple-combination CFTR modulator approved 2024 for cystic fibrosis. Alyftrek offers once-daily dosing (versus Trikafta's twice-daily schedule). International requests come from CF patients in MENA and India who want to transition from Trikafta to the once-daily regimen ahead of local registration.

Casgevy (exagamglogene autotemcel, co-developed with CRISPR Therapeutics)

CRISPR-Cas9-based autologous gene-editing therapy approved for sickle cell disease (in patients 12 and older with recurrent vaso-occlusive crises) and for transfusion-dependent beta-thalassemia. Reserve Meds does not coordinate Casgevy for direct delivery because the autologous-cell-collection, ex-vivo CRISPR editing, and reinfusion logistics anchor delivery to a US Vertex-authorized treatment center; we redirect those inquiries to medical-travel pathway documentation.

Journavx (suzetrigine)

First-in-class selective sodium channel Nav1.8 inhibitor approved 2025 for moderate to severe acute pain in adults. Journavx is the first non-opioid systemic acute pain medication with a novel mechanism in over twenty years. International requests come from post-operative and post-injury acute pain patients in MENA and India seeking a non-opioid alternative.

Kalydeco (ivacaftor)

Single-CFTR-modulator ivacaftor monotherapy approved for cystic fibrosis patients age 1 month and older with at least one ivacaftor-responsive mutation. Cross-border requests come from very young pediatric CF patients (under 2) and from patients with the specific CFTR mutations responsive only to ivacaftor monotherapy.

Symdeko (tezacaftor and ivacaftor) and Orkambi (lumacaftor and ivacaftor)

Older-generation CFTR modulator combinations. Demand has shifted to Trikafta and Alyftrek, but specific patients on long-term continuity of care still route through Reserve Meds.

Why patients route Vertex products through cross-border NPP

Three patterns dominate. First, cystic fibrosis CFTR modulator access in MENA and India is constrained by intermittent supply, narrow pediatric registration, and payer formularies that may cover only one of the CFTR modulators. Second, Casgevy and the CRISPR gene-editing pathway is structurally US-anchored for the autologous workflow; Reserve Meds supports the pre-trip preparation and US-treatment-center introduction. Third, Journavx is too new globally for non-US labels. The Vertex Patient Services support program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Vertex-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Vertex distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Vertex market access teams: Reserve Meds maintains structured demand visibility across the CF CFTR modulator franchise, the Casgevy medical-travel pathway, and the Journavx acute pain launch. If your group is sizing pre-registration or cross-border supplemental demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the Vertex portfolio

The CF CFTR modulator franchise concentrates in pediatric pulmonology centers in the UAE, Saudi Arabia, India, Egypt, and Kuwait where CF patient registries are established. Casgevy medical-travel originates predominantly from sickle cell disease populations in Saudi Arabia, India, Egypt, and the Gulf, and from transfusion-dependent beta-thalassemia populations in India, Egypt, and the Eastern Mediterranean. Journavx demand is broad-based across the region.

What Reserve Meds provides

For every Vertex product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Vertex product and want a firm quote can start a request below.

Start a request for a Vertex product

Next step for Vertex teams

If you are on the Vertex access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.